Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Press release dated May 26, 2022 titled 'Zydus Lifesciences receives final approval from USFDA for Pemetrexed for Injection'26-05-2022
26-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper Publication of Notice of loss of share certificate of the Company, published in the Financial Express English and Gujarati Editions, both on May 26, 202226-05-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate26-05-2022
Zydus Lifesciences Ltd - 532321 - Public Announcement On Buyback
Public Announcement on Buyback published in newspapers24-05-2022
Zydus Lifesciences Ltd - 532321 - Board Resolution Approving Buyback
Board Resolution dated May 20, 2022 approving the buyback issue21-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper cutting with regard to publication of extracts of audited financial results for the quarter / year ended on March 31, 2022 in Financial Express on May 21, 2022.21-05-2022
Zydus Lifesciences Ltd - 532321 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Annual Secretarial Compliance Certificate issued by Manoj Hurkat & Associates, Practicing Company Secretaries for the financial year ended on March 31, 2022.20-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The audio recording of the Company's Investor Call to discuss the financial results for the quarter and year ended March 31, 202220-05-2022
Zydus Lifesciences Ltd - 532321 - Promoters Intention Letters
Promoters intention letters to participate in the buyback.20-05-2022
Zydus Lifesciences Ltd - 532321 - Announcement under Regulation 30 (LODR)-Appointment of Statutory Auditor/s
Re-appointment of Deloitte as the Statutory Auditors subject to the approval of the shareholders at the ensuing annual general meeting20-05-2022